Search
Cyclophosphamide Treatment Options in Pennsylvania
A collection of 416 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Pennsylvania, United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
337 - 348 of 416
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Completed
This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2016
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
Completed
Amrubicin has shown single-agent activity in lung cancer. The combination of cyclophosphamide and anthracyclines has been studied and concluded that the combination was tolerable, could be given safely, and therapeutically useful.
This Phase I study will evaluate the combination of cyclophosphamide with amrubicin in relapsed solid tumors and will define the MTD of the combination in a US population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2015
Locations: Fox Chase Cancer Center Extramural Research Program, Rockledge, Pennsylvania
Conditions: Lung Cancer
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS)... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/18/2015
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Central Nervous System Tumor, Pediatric
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
Terminated
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/02/2015
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Melanoma (Skin)
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have newly diagnosed brain tumor.
Gender:
ALL
Ages:
10 years and below
Trial Updated:
11/30/2015
Locations: Milton S. Hershey Medical Center, Hershey, Pennsylvania +1 locations
Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone.
A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Univ. of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Non-small Cell Lung Cancer
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Completed
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells. Giving chemotherapy or radiation therapy before or after transplant also stops the patient's immune system from rejecting the donor's bone marrow stem cells. The donated stem cells may replace the patient's immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the... Read More
Gender:
ALL
Ages:
Between 6 months and 74 years
Trial Updated:
09/02/2015
Locations: Hahnemann University Hospital, Philadelphia, Pennsylvania
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma.
PURPOSE: Randomized phase III tri... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2015
Locations: CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania +3 locations
Conditions: Multiple Myeloma
Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by autologous bone marrow transplantation in treating patients with chronic myelogenous leukemia.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/13/2015
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
Conditions: Leukemia
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Terminated
This phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2015
Locations: Butler Memorial Hospital, Butler, Pennsylvania +4 locations
Conditions: Refractory Multiple Myeloma
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Giving imatinib mesylate together with chemotherapy and peripheral ste... Read More
Gender:
ALL
Ages:
Between 15 years and 59 years
Trial Updated:
11/13/2014
Locations: Western Pennsylvania Hospital, Pittsburgh, Pennsylvania
Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
Terminated
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving combination chemotherapy after surgery may kill any remaining tumor cells.
PURPOSE: This phase II trial is studying how well surgery and/or combination chemotherapy work in treating children with fibrosarcoma.
Gender:
ALL
Ages:
2 years and below
Trial Updated:
09/16/2014
Locations: Geisinger Medical Center, Danville, Pennsylvania +2 locations
Conditions: Sarcoma
337 - 348 of 416